Global Leading Market Research Publisher QYResearch announces the release of its latest report “Therapeutic Ultrasound Devices – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.
The scalpel, for all its precision, remains a tool of mechanical destruction—it cuts through healthy tissue to reach diseased tissue, leaving trauma in its therapeutic wake. For decades, this trade-off between access and injury was accepted as a surgical inevitability. Therapeutic ultrasound devices have fundamentally altered this calculus. By converting electrical energy into focused acoustic energy that can traverse intervening tissue without incision, then depositing thermal, mechanical, or physicochemical effects precisely at the target site, these systems have created an entirely new therapeutic paradigm: treat the disease while leaving the patient intact. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Therapeutic Ultrasound Devices market, delivering the strategic intelligence on HIFU tumor ablation systems, intravascular ultrasound devices, focused ultrasound aesthetics platforms, and ultrasound physical therapy equipment that medical device executives, healthcare investors, and hospital procurement strategists require to navigate one of medtech’s most technologically dynamic and commercially consequential sectors.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6700582/therapeutic-ultrasound-devices
The global market for Therapeutic Ultrasound Devices was estimated to be worth USD 5,421 million in 2025 and is projected to reach USD 8,932 million by 2032, advancing at a robust CAGR of 7.4% from 2026 to 2032. This growth trajectory reflects the convergence of powerful structural tailwinds: China’s 217 million population aged 65 and above is driving rigid, non-discretionary demand for degenerative disease treatments; breakthroughs in high-intensity focused ultrasound (HIFU) are expanding the addressable oncology population; regulatory innovation is accelerating market access for domestic devices in previously import-dominated segments; and the medical aesthetics boom is creating an entirely new mass-market application layer for focused ultrasound technology.
Product Definition and Technology Architecture
Therapeutic ultrasound devices refer to medical device systems that utilize the mechanical effects (cavitation, acoustic streaming, tissue fragmentation), thermal effects (coagulative necrosis, hyperthermia), and physicochemical effects (sonoporation, sonodynamic activation) of ultrasound to treat human diseases. According to the Medical Device Classification Catalog of China’s National Medical Products Administration (NMPA), therapeutic ultrasound devices span multiple regulatory categories: high-intensity focused ultrasound (HIFU) systems for tumor ablation delivering acoustic intensities sufficient to cause coagulative necrosis of deep-seated lesions without damaging overlying tissues; surgical ultrasound devices for tissue dissection, vessel sealing, and phacoemulsification in ophthalmology; ultrasound therapy devices for physical rehabilitation applying low-intensity continuous or pulsed ultrasound to stimulate tissue repair, reduce inflammation, and manage pain; and focused ultrasound skin treatment devices for aesthetic medicine applications including fat reduction and skin tightening.
The core working principle is elegantly physical: electrical energy drives piezoelectric transducer elements that vibrate at specific frequencies—typically 0.5 to 10 MHz depending on application—to generate ultrasonic waves. These waves are focused geometrically or electronically using phased-array beamforming techniques to converge at a target volume, where the acoustic energy converts to thermal or mechanical effects. The fundamental clinical value proposition of non-invasive therapeutic ultrasound is its ability to treat disease at depth without traversing the body surface with instruments, radiation, or incisions—eliminating the access-related morbidity, infection risk, scarring, and recovery time that accompany conventional open and laparoscopic surgery.
The Strategic Landscape: Domestic Substitution, Regulatory Breakthroughs, and Technology Frontiers
The competitive dynamics of the ultrasound medical device industry are being reshaped by three structural forces that carry profound implications for market share allocation over the forecast period.
The domestic substitution imperative. China’s domestic ultrasound equipment market share reached 65% in 2025, a milestone that reflects both policy support for indigenous medical device innovation and the technological maturation of domestic manufacturers. Mindray Medical’s ultra-high-end ultrasound Resona A20, priced 100% higher than its predecessor, demonstrates that domestic brands are no longer confined to the value segment but are competing on technology leadership—with FDA approval planned for 2025 representing a global market access inflection point. Of the 281 innovative medical devices approved by the NMPA in 2024, 245 were domestic products. United Imaging plans to launch its full ultrasound product line at the RSNA conference in December 2025, expanding into overseas markets. This domestic substitution wave is most advanced in diagnostic ultrasound but is rapidly extending to therapeutic applications.
Regulatory-driven market creation. In February 2026, the NMPA approved China’s first intravascular ultrasound guidewire system for interventional treatment of chronic total occlusion of coronary arteries, filling a critical technology gap in intravascular therapeutic ultrasound. In December 2025, Peninsula Medical released the country’s first Class III focused ultrasound skin treatment device, with nearly 6,000 hospitals already covering similar products, driving industry standardization in the medical aesthetics segment. Regulators have simultaneously clarified treatment boundaries: focused ultrasound is approved for fat reduction, while its use for facial wrinkles and skin tightening remains off-label—a compliance distinction that creates both market discipline and market opportunity for manufacturers who pursue formal indication expansion through clinical trials.
Clinical evidence expansion. On the technology innovation front, HIFU is achieving clinical breakthroughs. The first human clinical trial in November 2025 demonstrated that a novel HIFU device combined with nanomicellar epirubicin for advanced abdominal tumors achieved a disease control rate of 66.7% with no Grade 3 or higher adverse events—a safety-efficacy profile that could substantially expand the addressable oncology population for HIFU beyond its current niche indications. In oncology, novel modalities such as sonodynamic therapy are expanding the therapeutic frontier, with HIFU combined with sonosensitizers showing potential to improve prognosis for patients with refractory tumors.
Technology Challenges: Component Sovereignty and Tariff Headwinds
Core technologies and components for high-end ultrasound equipment have long been dominated by foreign brands, with gaps still existing in the ultra-high-end segment. The escalation of U.S.-China tariff disputes in 2025—with China imposing a 34% tariff on medical imaging equipment from the United States and the U.S. doubling tariffs on Chinese semiconductors to 50%—has driven up procurement costs for imported systems and components while simultaneously accelerating the development of localized supply chains for ultrasound transducers, high-voltage amplifiers, and beamforming electronics. The Hainan Free Trade Port’s zero-tariff policy provides a buffer for imported high-end equipment while simultaneously driving technological iteration in the domestic supply base—a dual-track strategy that balances near-term clinical access against long-term industrial capability development.
Regional Dynamics and Demand Evolution
North America leads cutting-edge innovation in HIFU, sonodynamic therapy, and related fields with its mature R&D ecosystem, having hosted the first human clinical trial of HIFU combined with sonosensitizers in November 2025. Europe maintains technological advantages in ultrasound surgical equipment and core component development. The Asia-Pacific region shows the most active growth, with China becoming a global focal point driven by policy support and domestic substitution. Central to this growth is an unmistakable demographic reality: 217 million citizens aged 65 and above are driving rigid, structural demand for treatments addressing degenerative musculoskeletal, cardiovascular, and oncological conditions—the very disease categories where therapeutic ultrasound offers its most compelling clinical value proposition.
Competitive Landscape and Market Segments
Key players span global medical device conglomerates, specialized therapeutic ultrasound innovators, and ascendant Chinese domestic manufacturers: Zimmer, ZetrOZ, SonaCare Medical, Richmar, Mettler Electronics, DJO Global, Enraf-Nonius, EDAP TMS, BTL Industries, Alpinion, Theraclion, Sonablate, Insightec, Classys, Profound Medical, EMS Physio, Ito Physical Therapy, Mindray Medical, Peninsula Medical, United Imaging, Sonoscape, Sonka Medical, and Wikkon.
Segment by Type
- Non-Invasive Therapeutic Ultrasound: HIFU tumor ablation, focused ultrasound aesthetics, transcranial focused ultrasound.
- Minimally Invasive Therapeutic Ultrasound: Laparoscopic and endoscopic ultrasound surgical devices.
- Intravascular Therapeutic Ultrasound: Catheter-based ultrasound for cardiovascular intervention.
Segment by Application
- Oncology: HIFU ablation of liver, pancreatic, prostate, and bone tumors; sonodynamic therapy.
- Urology: Prostate HIFU, kidney stone lithotripsy.
- Cardiovascular: Intravascular ultrasound guidewire systems for chronic total occlusion intervention.
- Medical Aesthetics: Focused ultrasound fat reduction, skin tightening.
- Musculoskeletal Rehabilitation: Low-intensity ultrasound for fracture healing, tendinopathy, and soft tissue repair.
Strategic Outlook
The therapeutic ultrasound devices market at USD 5,421 million in 2025 projecting to USD 8,932 million by 2032 reflects the structural expansion of non-invasive and minimally invasive therapeutic paradigms across oncology, cardiovascular intervention, medical aesthetics, and rehabilitation. The demand for ultrasound treatment equipment in primary medical institutions continues to grow with the implementation of tiered diagnosis and treatment systems, though a shortage of specialized clinical talent constrains technology deployment effectiveness—creating a parallel market opportunity for AI-assisted treatment planning and automated ultrasound guidance systems. The manufacturers positioned for above-market value capture are those mastering the intersection of phased-array transducer technology, real-time treatment monitoring through MR or ultrasound thermometry, and the clinical evidence generation that secures indication expansion and guideline inclusion across the multiple specialties where therapeutic ultrasound is progressively replacing more invasive alternatives.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
